Depletion of Anti-CD47mAb in Plasma by Genetically Modified Cells for Pre-transfusion Testing
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Velliquette R, Aeschlimann J, Kirkegaard J, Shakarian G, Lomas-Francis C, Westhoff C
. Monoclonal anti-CD47 interference in red cell and platelet testing. Transfusion. 2018; 59(2):730-737.
DOI: 10.1111/trf.15033.
View
2.
Ehrend E, Manns P, Harenkamp S, Seifried E, Geisen C, Bonig H
. Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing. Blood. 2021; 138(9):814-817.
PMC: 8414259.
DOI: 10.1182/blood.2021011396.
View
3.
Du C, Sui W, Huang H, Zhang Y, Ding X, Gao C
. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment. Leuk Res. 2022; 122:106953.
DOI: 10.1016/j.leukres.2022.106953.
View
4.
Mei Z, Wool G
. Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing. Hematol Oncol Clin North Am. 2019; 33(5):797-811.
DOI: 10.1016/j.hoc.2019.05.007.
View
5.
Zhang W, Huang Q, Xiao W, Zhao Y, Pi J, Xu H
. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis. Front Immunol. 2020; 11:18.
PMC: 7003246.
DOI: 10.3389/fimmu.2020.00018.
View